Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway

Cancer Biology and Therapy

Volumn 15, Issue 5, 2014, Pages 524-532

  Edling, Charlotte E ^a   Selvaggi, Federico ^a   Ghonaim, Ragheda ^a   Maffucci, Tania ^a   Falasca, Marco ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Caffeine; CGS 15943; Hepatocellular carcinoma; Pancreatic ductal adenocarcinoma; Phosphoinositide 3 kinase

Indexed keywords

9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; CAFFEINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; 9-CHLORO-2-(2-FURYL)-(1,2,4)TRIAZOLO(1,5-C)QUINAZOLIN-5-IMINE; ADENOSINE RECEPTOR STIMULATING AGENT; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; TRIAZOLE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL COUNTING; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; DRUG EFFECTS; LIVER TUMOR; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CAFFEINE; CARCINOMA, HEPATOCELLULAR; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PURINERGIC P1 RECEPTOR AGONISTS; QUINAZOLINES; SIGNAL TRANSDUCTION; TRIAZOLES;

EID: 84899863836     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28018     Document Type: Article

References (69)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379:1245-55; PMID:22353262; http://dx.doi.org/10.1016/S0140-6736(11)61347-0
2. Di Bisceglie AM, Carithers RL Jr., Gores GJ. Hepatocellular carcinoma. Hepatology 1998; 28:1161-5; PMID:9755258; http://dx.doi.org/10.1002/hep. 510280436 (Pubitemid 28450282)
3. Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9:191-211, v; PMID:15831268; http://dx.doi.org/10.1016/j.cld.2004.12.009
4. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6:674-87; PMID:16929323; http://dx.doi.org/10.1038/nrc1934 (Pubitemid 44286000)
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/ 10.3322/caac.20107
6. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142:1264-73, e1; PMID:22537432; http://dx.doi.org/10.1053/j.gastro.2011.12.061
7. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997; 350:1142-3; PMID:9343506; http://dx.doi.org/10.1016/S0140-6736(05)63789-0 (Pubitemid 27454010)
8. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998; 351:214-5; PMID:9449893; http://dx.doi.org/10.1016/S0140- 6736(05)78179-4
9. Singh S, Singh PP, Roberts LR, Sanchez W. Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2014; 11:45-54; PMID:23938452; http://dx.doi.org/10.1038/nrgastro.2013.143
10. Kuper H, Tzonou A, Kaklamani E, Hsieh CC, Lagiou P, Adami HO, Trichopoulos D, Stuver SO. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer 2000; 85:498-502; PMID:10699921; http://dx.doi.org/10.1002/(SICI)1097-0215(20000215) 85:4<498::AID-IJC9>3.0.CO;2-F (Pubitemid 30075127)
11. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010; 28:3994-4005; PMID:20679622; http://dx.doi.org/10. 1200/JCO.2010.28.7805
12. Ryder SD; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52(Suppl 3):iii1-8; PMID:12692148; http://dx.doi.org/10.1136/gut.52.suppl-3.iii1 (Pubitemid 36520856)
13. Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol 2008; 15:1008-14; PMID:18236117; http://dx.doi.org/10.1245/s10434-007-9705-0
14. Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H, Sakata R, Fujita Y, Ichikawa S, Iwai N, et al.; JACC Study Group. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 2005; 93:607-10; PMID:16091758; http://dx.doi.org/10.1038/sj.bjc.6602737 (Pubitemid 43080007)
15. Gallus S, Bertuzzi M, Tavani A, Bosetti C, Negri E, La Vecchia C, Lagiou P, Trichopoulos D. Does coffee protect against hepatocellular carcinoma? Br J Cancer 2002; 87:956-9; PMID:12434283; http://dx.doi.org/10.1038/sj.bjc.6600582 (Pubitemid 35305644)
16. Bravi F, Bosetti C, Tavani A, Bagnardi V, Gallus S, Negri E, Franceschi S, La Vecchia C. Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology 2007; 46:430-5; PMID:17580359; http://dx.doi.org/10. 1002/hep.21708 (Pubitemid 47344778)
17. Gelatti U, Covolo L, Franceschini M, Pirali F, Tagger A, Ribero ML, Trevisi P, Martelli C, Nardi G, Donato F; Brescia HCC Study Group. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 2005; 42:528-34; PMID:15868652; http://dx.doi.org/10.1016/j.jhep.2004.11.039 (Pubitemid 40342932)
18. Inoue M, Yoshimi I, Sobue T, Tsugane S; JPHC Study Group. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005; 97:293-300; PMID:15713964; http://dx.doi.org/10.1093/jnci/dji040 (Pubitemid 40310277)
19. Weinberg BA, Bealer BK, eds. The world of caffeine: the science and culture of the world's most popular drug. New York:Routledge, 2001.
20. Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H, Sakata R, Fujita Y, Ichikawa S, Iwai N, et al. Dietary habits and risk of death due to hepatocellular carcinoma in a large scale cohort study in Japan. Univariate analysis of JACC study data. Kurume Med J 2004; 51:141-9; PMID:15373231; http://dx.doi.org/10.2739/kurumemedj.51.141 (Pubitemid 39106858)
21. Shimazu T, Tsubono Y, Kuriyama S, Ohmori K, Koizumi Y, Nishino Y, Shibuya D, Tsuji I. Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer 2005; 116:150-4; PMID:15756689; http://dx.doi.org/10.1002/ijc.20989 (Pubitemid 40827769)
22. Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005; 129:1928-36; PMID:16344061; http://dx.doi.org/10.1053/j.gastro.2005.08.056 (Pubitemid 41772970)
23. Okano J, Nagahara T, Matsumoto K, Murawaki Y. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway. Basic Clin Pharmacol Toxicol 2008; 102:543-51; PMID:18346049; http://dx.doi.org/10.1111/j.1742-7843.2008.00231.x (Pubitemid 351691962)
24. He Z, Ma WY, Hashimoto T, Bode AM, Yang CS, Dong Z. Induction of apoptosis by caffeine is mediated by the p53, Bax, and caspase 3 pathways. Cancer Res 2003; 63:4396-401; PMID:12907610 (Pubitemid 36951009)
25. Rothwell K. Dose-related inhibition of chemical carcinogenesis in mouse skin by caffeine. Nature 1974; 252:69-70; PMID:4427686; http://dx.doi.org/10. 1038/252069a0
26. Nishikawa A, Furukawa F, Imazawa T, Ikezaki S, Hasegawa T, Takahashi M. Effects of caffeine on glandular stomach carcinogenesis induced in rats by N-methyl-N'-nitro-N-nitrosoguanidine and sodium chloride. Food Chem Toxicol 1995; 33:21-6; PMID:7821872; http://dx.doi.org/10.1016/0278-6915(95)80243-6
27. Theiss JC, Shimkin MB. Inhibiting effect of caffeine on spontaneous and urethan-induced lung tumors in strain A mice. Cancer Res 1978; 38:1757-61; PMID:647685 (Pubitemid 8349725)
28. VanderPloeg LC, Welsch CW. Inhibition by caffeine of ovarian hormone-induced mammary gland tumorigenesis in female GR mice. Cancer Lett 1991; 56:245-50; PMID:2021928; http://dx.doi.org/10.1016/0304-3835(91)90009-7
29. Tolmach LJ, Jones RW, Busse PM. The action of caffeine on X-irradiated HeLa cells. I. Delayed inhibition of DNA synthesis. Radiat Res 1977; 71:653-65; PMID:897091; http://dx.doi.org/10.2307/3574633 (Pubitemid 8200769)
30. Dillehay LE, Chang G, Williams JR. Effects of methylxanthines on cell-cycle redistribution and sensitization to killing by low-dose-rate radiation. NCI Monogr 1988; 6:173-6; PMID:2451134 (Pubitemid 18047984)
31. Boonkitticharoen V, Laohathai K, Puribhat S. Differential radiosensitization of radioresistant human cancer cells by caffeine. J Med Assoc Thai 1993; 76:271-7; PMID:8006558 (Pubitemid 24295825)
32. Busse PM, Bose SK, Jones RW, Tolmach LJ. The action of caffeine on X-irradiated HeLa cells. II. Synergistic lethality. Radiat Res 1977; 71:666-77; PMID:911393; http://dx.doi.org/10.2307/3574634 (Pubitemid 8200770)
33. Busse PM, Bose SK, Jones RW, Tolmach LJ. The action of caffeine on X-irradiated HeLa cells. III. Enhancement of X-ray-induced killing during G2 arrest. Radiat Res 1978; 76:292-307; PMID:156382; http://dx.doi.org/10.2307/ 3574780 (Pubitemid 9037669)
34. Fujimaki S, Matsuda Y, Wakai T, Sanpei A, Kubota M, Takamura M, Yamagiwa S, Yano M, Ohkoshi S, Aoyagi Y. Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling. Cancer Lett 2012; 319:98-108; PMID:22265862; http://dx.doi.org/10.1016/j.canlet. 2011.12.043
35. Kawano Y, Nagata M, Kohno T, Ichimiya A, Iwakiri T, Okumura M, Arimori K. Caffeine increases the antitumor effect of Cisplatin in human hepatocellular carcinoma cells. Biol Pharm Bull 2012; 35:400-7; PMID:22382328; http://dx.doi.org/10.1248/bpb.35.400
36. Chae S, Kim YB, Lee JS, Cho H. Resistance to paclitaxel in hepatoma cells is related to static JNK activation and prohibition into entry of mitosis. Am J Physiol Gastrointest Liver Physiol 2012; 302:G1016-24; PMID:22323130; http://dx.doi.org/10.1152/ajpgi.00449.2011
37. Miura Y, Ono K, Okauchi R, Yagasaki K. Inhibitory effect of coffee on hepatoma proliferation and invasion in culture and on tumor growth, metastasis and abnormal lipoprotein profiles in hepatoma-bearing rats. J Nutr Sci Vitaminol (Tokyo) 2004; 50:38-44; PMID:15228216; http://dx.doi.org/10.3177/jnsv.50.38 (Pubitemid 38405207)
38. Ito K, Nakazato T, Miyakawa Y, Yamato K, Ikeda Y, Kizaki M. Caffeine induces G2/M arrest and apoptosis via a novel p53-dependent pathway in NB4 promyelocytic leukemia cells. J Cell Physiol 2003; 196:276-83; PMID:12811820; http://dx.doi.org/10.1002/jcp.10289 (Pubitemid 36775874)
39. Hashimoto T, He Z, Ma WY, Schmid PC, Bode AM, Yang CS, Dong Z. Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. Cancer Res 2004; 64:3344-9; PMID:15126379; http://dx.doi.org/10.1158/0008-5472.CAN-03-3453 (Pubitemid 38581442)
40. Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J, Shepherd PR. Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J Biol Chem 2002; 277:37124-30; PMID:12145276; http://dx.doi.org/10.1074/jbc. M202101200
41. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoformspecific PI3K signalling. Nat Rev Mol Cell Biol 2010; 11:329-41; PMID:20379207; http://dx.doi.org/10.1038/nrm2882
42. Falasca M, Maffucci T. Regulation and cellular functions of class II phosphoinositide 3-kinases. Biochem J 2012; 443:587-601; PMID:22507127; http://dx.doi.org/10.1042/BJ20120008
43. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008; 133:403-14; PMID:18455982; http://dx.doi.org/10.1016/j.cell.2008.04. 013 (Pubitemid 351622014)
44. Keniry M, Parsons R. The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 2008; 27:5477-85; PMID:18794882; http://dx.doi.org/10.1038/onc.2008.248
45. Vinciguerra M, Foti M. PTEN at the crossroad of metabolic diseases and cancer in the liver. Ann Hepatol 2008; 7:192-9; PMID:18772845
46. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 2011; 13:224; PMID:22114931; http://dx.doi.org/10.1186/bcr3039
47. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010; 29:4989-5005; PMID:20639898; http://dx.doi.org/10.1038/onc.2010.236
48. Thompson JE, Thompson CB. Putting the rap on Akt. J Clin Oncol 2004; 22:4217-26; PMID:15483033; http://dx.doi.org/10.1200/JCO.2004.01.103 (Pubitemid 41185193)
49. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4:988-1004; PMID:16341064; http://dx.doi.org/10.1038/nrd1902
50. Falasca M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des 2010; 16:1410-6; PMID:20166984; http://dx.doi.org/10.2174/138161210791033950
51. Falasca M. Phosphoinositide 3-kinase pathway inhibitors: pharmacology, metabolism & drug development. Curr Med Chem 2011; 18:2673; PMID:21649576; http://dx.doi.org/10.2174/092986711796011210
52. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008; 27:5486-96; PMID:18794883; http://dx.doi.org/10.1038/onc.2008.244
53. Edling CE, Selvaggi F, Buus R, Maffucci T, Di Sebastiano P, Friess H, Innocenti P, Kocher HM, Falasca M. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res 2010; 16:4928-37; PMID:20876794; http://dx.doi.org/10.1158/1078-0432.CCR-10-1210
54. Dituri F, Mazzocca A, Lupo L, Edling CE, Azzariti A, Antonaci S, Falasca M, Giannelli G. PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma. Int J Cancer 2012; 130:2505-13; PMID:21796621; http://dx.doi.org/10.1002/ijc.26319
55. Guerreiro AS, Fattet S, Kulesza DW, Atamer A, Elsing AN, Shalaby T, Jackson SP, Schoenwaelder SM, Grotzer MA, Delattre O, et al. A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance. Mol Cancer Res 2011; 9:925-35; PMID:21652733; http://dx.doi.org/10.1158/1541-7786.MCR-10-0200
56. Brazzatti JA, Klingler-Hoffmann M, Haylock-Jacobs S, Harata-Lee Y, Niu M, Higgins MD, Kochetkova M, Hoffmann P, McColl SR. Differential roles for the p101 and p84 regulatory subunits of PI3Kγ in tumor growth and metastasis. Oncogene 2012; 31:2350-61; PMID:21996737; http://dx.doi.org/10.1038/onc.2011.414
57. Falasca M, Selvaggi F, Buus R, Sulpizio S, Edling CE. Targeting phosphoinositide 3-kinase pathways in pancreatic cancer-from molecular signalling to clinical trials. Anticancer Agents Med Chem 2011; 11:455-63; PMID:21521159; http://dx.doi.org/10.2174/187152011795677382
58. Hildebrand JS, Patel AV, McCullough ML, Gaudet MM, Chen AY, Hayes RB, Gapstur SM. Coffee, tea, and fatal oral/pharyngeal cancer in a large prospective US cohort. Am J Epidemiol 2013; 177:50-8; PMID:23230042; http://dx.doi.org/10. 1093/aje/kws222
59. Uccella S, Mariani A, Wang AH, Vierkant RA, Cliby WA, Robien K, Anderson KE, Cerhan JR. Intake of coffee, caffeine and other methylxanthines and risk of Type I vs Type II endometrial cancer. Br J Cancer 2013; 109:1908-13; PMID:24022184; http://dx.doi.org/10.1038/bjc.2013.540
60. Song F, Qureshi AA, Han J. Increased caffeine intake is associated with reduced risk of basal cell carcinoma of the skin. Cancer Res 2012; 72:3282-9; PMID:22752299; http://dx.doi.org/10.1158/0008-5472.CAN-11-3511
61. Miura K, Hughes MC, Green AC, van der Pols JC. Caffeine intake and risk of basal cell and squamous cell carcinomas of the skin in an 11-year prospective study. Eur J Nutr 2013; (Forthcoming); PMID:23824258; http://dx.doi.org/10. 1007/s00394-013-0556-0
62. Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 2013; 11:1413-1421; PMID:23660416; http://dx.doi.org/10.1016/j.cgh.2013. 04.039
63. Johnson S, Koh WP, Wang R, Govindarajan S, Yu MC, Yuan JM. Coffee consumption and reduced risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Cancer Causes Control 2011; 22:503-10; PMID:21258859; http://dx.doi.org/10.1007/s10552-010-9725-0
64. Fujise Y, Okano J, Nagahara T, Abe R, Imamoto R, Murawaki Y. Preventive effect of caffeine and curcumin on hepato-carcinogenesis in diethylnitrosamine- induced rats. Int J Oncol 2012; 40:1779-88; PMID:22293778
65. Ferk F, Huber WW, Grasl-Kraupp B, Speer K, Buchmann S, Bohacek R, Mišík M, Edelbauer L, Knasmüller S. Protective effects of coffee against induction of DNA damage and pre-neoplastic foci by aflatoxin B1. Mol Nutr Food Res 2013; (Forthcoming)
66. Gururajanna B, Al-Katib AA, Li YW, Aranha O, Vaitkevicius VK, Sarkar FH. Molecular effects of taxol and caffeine on pancreatic cancer cells. Int J Mol Med 1999; 4:501-7; PMID:10534572
67. Jang MH, Shin MC, Kang IS, Baik HH, Cho YH, Chu JP, Kim EH, Kim CJ. Caffeine induces apoptosis in human neuroblastoma cell line SK-N-MC. J Korean Med Sci 2002; 17:674-8; PMID:12378022
68. Lelo A, Miners JO, Robson R, Birkett DJ. Assessment of caffeine exposure: caffeine content of beverages, caffeine intake, and plasma concentrations of methylxanthines. Clin Pharmacol Ther 1986; 39:54-9; PMID:3943270; http://dx.doi.org/10.1038/clpt.1986.10 (Pubitemid 16166966)
69. Howell LL, Byrd LD. Effects of CGS 15943, a nonxanthine adenosine antagonist, on behavior in the squirrel monkey. J Pharmacol Exp Ther 1993; 267:432-9; PMID:8229772 (Pubitemid 23325037)